CAW
FOLD

Cornerstone Advisors (Washington)’s Amicus Therapeutics FOLD Stock Holding History

Cornerstone Advisors (Washington)’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-219
Closed -$3K – 1039
2019
Q2 		$3K Buy
+219
New +$2.78K ﹤0.01% 1030

Other funds holding FOLD

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Cornerstone Advisors (Washington)'s FOLD Position: Q3 2019 in Review

Cornerstone Advisors (Washington) sold out of Amicus Therapeutics (FOLD) in Q3 2019, closing a stake of 219 shares — an estimated $3K sold.

Cornerstone Advisors (Washington) first reported a position in FOLD in Q2 2019 and held it in 1 quarter. The position peaked at $3K in Q2 2019. 205 funds tracked by Wall St. Rank hold FOLD as of Q3 2019.

  • Cornerstone Advisors (Washington) reported no remaining Amicus Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Cornerstone Advisors (Washington) sold 219 Amicus Therapeutics shares in Q3 2019, an estimated $3K.
  • Cornerstone Advisors (Washington) first reported a position in Amicus Therapeutics in Q2 2019 and held it in 1 quarter.
  • Cornerstone Advisors (Washington)'s Amicus Therapeutics position peaked at $3K in Q2 2019.
  • 205 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q3 2019.

Based on Cornerstone Advisors (Washington)'s 13F filing for Q3 2019, filed 23 Oct 2019.